| Identification | Back Directory | [Name]
LX-2343 | [CAS]
333745-53-2 | [Synonyms]
LX-2343
LX2343;LX-2343;LX 2343
2-[N-(Benzenesulfonyl)-5-chloro-2-methoxyanilino]-N-(1,3-benzodioxol-5-yl)acetamide
Acetamide, N-1,3-benzodioxol-5-yl-2-[(5-chloro-2-methoxyphenyl)(phenylsulfonyl)amino]- | [Molecular Formula]
C22H19ClN2O6S | [MDL Number]
MFCD02578482 | [MOL File]
333745-53-2.mol | [Molecular Weight]
474.91 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:73.33(Max Conc. mg/mL);154.41(Max Conc. mM)
DMF:33.0(Max Conc. mg/mL);69.49(Max Conc. mM) | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
LX-2343, is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. It has also shown activity as a non-ATP competitive PI3K inhibitor. LX2343 stimulates autophagy in its promotion of Aβ clearance. | [in vivo]
APP/PS1 mice express chimeric human Swedish mutant APP and a mutant human presenilin 1 protein and are widely used as an effective animal model for AD dementia. The amelioration of memory impairment by LX2343 is evaluated t in this model using the MWM test. In 8-d training trials, the path lengths and escape latencies used to find the platform for APP/PS1 transgenic mice are remarkably longer than those for non-transgenic mice, while 10 mg/kg LX2343 administration obviously antagonizes the prolonged path lengths and escape latencies at d 7 and 8. In the probe trial assay, the LX2343-administered transgenic mice cross over the hidden location of the platform more frequently compared with the vehicle-administered transgenic mice[1]. | [IC 50]
BACE1: 11.43 μM (IC50); PI3K: 15.99 μM (IC50); Aβ; Autophagy |
|
|